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Jin-Tae Kwon, Tae-Eun Jung and Dong-Hyup Lee*Abstract
We report a case of acute thrombosis of bioprosthetic mitral valve in a 59 year–old Korean female, who underwent
a mitral valve replacement with a 25 mm Carpentier - Edwards PERIMOUNT Plus bioprosthesis (Edwards
Lifesciences, Inc.; Irvine, CA, USA) and a mini-Maze procedure for correction of mitral stenosis (MS) and atrial
fibrillation (AF). On the 10th postoperative day, the patient began to complain of increasing dyspnea and general
malaise. Her symptoms worsened and developed into pulmonary edema. Echocardiography revealed a mean
diastolic pressure gradient (MDPG) of 10 mmHg across the mitral valve and pressure-half time (PHT) of 166 msec.
Due to progressive decompensated heart failure, the patient underwent a repeat sternotomy to replace the
bioprosthetic mitral valve. Intraoperatively, we found a thrombosis around the bioprosthetic mitral valve. We
excised the bioprosthetic mitral valve and replaced it with a 27 mm ATS mechanical valve (ATS medical, Inc.;
Minneapolis, MN, USA). We experienced a rare case that required an early reoperation for a thrombosis of the
bioprosthetic valve.
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The advantage of using a bioprosthetic valve over a mech-
anical valve is that it lowers the incidence of thrombosis,
avoiding the need for anticoagulant medication in the long
term.
The reported incidence of bioprosthetic valve thrombosis
on routine echocardiography surveillance is approximately
6% [1]. However, the occurrence of acute thrombosis of
the bioprosthetic mitral valves during the early postopera-
tive period is rare.
We experienced a rare case requiring an early reoperation
for a thrombosis of the bioprosthetic valve.Case presentation
A 59-year old Korean female was referred with shortness
of breath. She was diagnosed with moderate mitral sten-
osis (MS, valve area: 1.07 cm2 by 2D) and atrial fibrillation
(AF). Preoperative echocardiography showed a large left
atrium (LAVolume Index: 81 ml / m2).
She underwent preservation of the sub-valvular appar-
atus of posterior leaflet of the mitral valve and replace-
ment with a 25 mm Carpentier – Edwards PERIMOUNT
Plus bioprosthesis (Edwards Lifesciences, Inc.; Irvine, CA,* Correspondence: dhlee@med.yu.ac.kr
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reproduction in any medium, provided the orUSA) and a mini-Maze procedure. Due to her history of
hemorrhagic stroke, we selected the bioprosthetic valve in
order to avoid anticoagulation. Her body surface area
(BSA) was 1.72 m2. The intraoperative transesophageal
echocardiogram after the first valve replacement shows no
evidence of leaflet entrapment, and bypass weaning was
uneventful.
A post operative electrocardiogram showed sinus
rhythm. On the first postoperative day, the patient was
started on an anticoagulant with Coumadin, and an
international normalized ratio (INR) of greater than 2
was reached on the sixth postoperative day. Recovery
was uneventful and on the second postoperative day, the
patient was transferred to the ward. After a transfer to
the general ward, the patient complained of mild dys-
pnea on exertion; however, sinus rhythm was still
present on an electrocardiogram. On the 10th postoper-
ative day, the patient began to complain of increasing
dyspnea and general malaise. During the next night, her
symptoms worsened and developed into a left side
pleural effusion and interstitial edema (Figure 1). A
transthoracic echocardiography detected a mean dia-
stolic pressure gradient (MDPG) of 10 mmHg across the
mitral valve, but no thrombus in LA. The calculated
pressure-half time (PHT) was 166 msec (Figure 2). Clin-
ically, evidence of MS was observed. There was notd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chest x-ray. Postoperative sixth day chest x-ray (A). On the postoperative 12th day, chest x-ray showed interstitial edema (B).
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decreased from 57% to 46%, compared to the preopera-
tive ejection fraction.
The patient was started on intravenous diuretics and
inotropics. However, due to progressive decompensated
heart failure, a repeat sternotomy was performed on the
14th postoperative day. Intraoperatively, we observed a
thrombus on the bioprosthetic valve and on the poster-
ior left atrial wall (Figure 3). In addition, we noticed that
the motion of the valve leaflet was slightly restricted.
The bioprosthetic valve was removed and replaced with
a 27 mm ATS mechanical valve (ATS Medical, Inc.;
Minneapolis, MN, USA). Postoperatively, she showed an
improvement of symptoms, and repeat echocardiog-
raphy showed a MDPG of 3.7 mmHg, PHT of 69 msec,
a well functioning prosthetic valve, and no sign of
thrombosis. She was discharged on Coumadin with an
INR target of 2 to 2.5.Figure 2 Transthoracic echocardiogram. An increased mean diastolic pr
comparable transthoracic image depicting normalization of mean gradientDiscussion
A few studies on the diagnostic characteristics and man-
agement of late bioprosthetic valve thrombosis have
been reported.
Patients with bioprosthetic aortic or mitral valve re-
placement have high risk of thromboembolism during
the first 10 days [2]. However, within two weeks postoper-
atively, the occurrence of a thrombosis in bioprosthetic
mitral valves is very rare.
Some precipitating factors of the thrombotic process
include acting as an underlying coagulopathy, left ven-
tricular dysfunction, low cardiac output, atrial fibrilla-
tion, large LA size, and prior history of thromboembolic
events [3].
A few cases involving the preservation of the mitral
valve apparatus as a predisposing factor for bioprosthetic
valve thrombosis have been reported because a complete
preservation of the mitral valve apparatus during mitralessure gradient of 10 mmHg after BVR (A). Following reoperation, a
(B).
Figure 3 Thrombus is visible on the bioprosthetic valve.
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bioprosthetic thrombosis, although such incidences ap-
pear to be rare [4]. However, a complication of mitral
valve replacement, such as a left ventricular rupture
could be prevented by maintaining the tethering effect
of the intact subvalvular apparatus [5]. In addition, there
are isolated reports of bioprosthetic thrombosis after a
complete valve excision [3].
Incidence of thrombo-embolism associated with AF
ablation is reported to be between 0% and 7%; therefore,
the 2007 Heart Rhythm Society expert consensus state-
ment recommends a minimum period of two months of
warfarin anticoagulation [6]. Although the policy of postop-
erative anticoagulation are different in each heart center, it
took a long time for INR to reach 2.0 on the 6th postope-
rative day. We should have taken care of more optimal
anticoagulation. The American College of Cardiology/
American Heart Association (ACC/AHA) guidelines rec-
ommend an administration of warfarin for three months,
following bioprosthetic valve replacement (BVR) [7]. The
risk is particularly high in the first few days after surgery,
and many centers start UFH as soon as the risk of increased
surgical bleeding is reduced (usually within 24 to 48 h) with
maintenance of aPPT between 55 and 70 seconds. After an
overlap of UFH and warfarin for 3 to 5 days, UFH may be
discontinued when INR reaches 2.0 to 3.0 [7].
In our case, the patient had a large LA size, and under-
went posterior leaflet preservation and a mini-Maze pro-
cedure. In this case, even though multiple factors are
contributed to acute bioprosthetic thrombosis, we should
keep up with current anticoagulation guidelines following
the BVR and radioablative Maze procedure.
Further studies are needed in order to clarify the anti-
coagulation strategy after BVR.
Through this case, we also realized the importance of
postoperative echocardiographic surveillance in high risk
groups.Conclusions
The occurrence of bioprosthetic valve thrombosis is un-
common. However, there are some predisposing factors
of bioprosthetic valve thrombosis; these include under-
lying coagulopathy, left ventricle dysfunction, AF, large
LA size, prosthetic mismatch, and radioablative Maze
procedure.
Therefore, an anticoagulant medication should be
maintained and echocardiographic surveillance should
be considered for patients in high risk groups.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JK and TJ wrote the draft of the manuscript and obtained the written
consent. DL performed the literature review and participated in the
manuscript writing and helped to the final writing of the paper and gave
final approval of the manuscript. All authors have read and approved the
final manuscript.
Acknowledgements
This work was supported by the National Research Foundation of Korea
(NRF) grant funded by the Korea government (MSIP) (No.2005-0049417).
Received: 22 March 2013 Accepted: 27 August 2013
Published: 27 August 2013
Reference
1. Oliver JM, Galloge P, Gonzalez A, Dominguez FJ, Gamallo C, Mesa JM:
Bioprosthetic mitral valve thrombosis: clinical profile, Transesophageal
echocardiographic features, and follow-up after anticoagulant therapy.
J Am Soc Echocardiogr 1996, 9:691–699.
2. Magda H, James HC, Valentin F, William JP, Diane EG, Kent RB, Gordon KD,
Thomas AO, James RP, Francisco JP, Hartzell VS, Jeffrey JL: High risk of
thromboemboli early after bioprosthetic cardiac valve replacement. J Am
Coll Cardiol 1995, 25:1111–1119.
3. Thomas B, Carreras F, Borras X, Pons-Lladó G: An unusual case of
bioprosthetic mitral valve thrombosis. Ann Thorac Surg 2001, 72:259–261.
4. Korkolis DP, Passik CS, Marshalko SJ, Koullias GJ: Early bioprosthetic mitral
valve “pseudostenosis” after complete preservation of the native mitral
apparatus. Ann Thorac Surg 2002, 74:1689–1691.
5. Okita Y, Miki S, Veda Y, Tahata T, Saki T, Matsugama K: Mitral valve
replacement with maintenance of mitral annulopapillary muscle
continuity in patients with mitral stenosis. J Thorac Cardiovasc Surg 1994,
108:42–51.
6. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ
Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jakman W, Jais P,
Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL,
Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A,
Ruskin JN, Shemin RJ: HRS/EHRA/ECAS expert consensus statement on
catheter and surgical ablation of atrial fibrillation: recommendations for
personnel, policy, procedures and follow-up. A report of the heart
rhythm society (HRS) task force on catheter and surgical ablation of
atrial fibrillation. Hear Rhythm 2007, 4:816–861.
7. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD,
Gaasch WH, Lytle BW, Nishimura RA, O’Rourke RA, Otto CM, Shah PM,
Kwon et al. Journal of Cardiothoracic Surgery 2013, 8:185 Page 4 of 4
http://www.cardiothoracicsurgery.org/content/8/1/185Shanewise JS: 2008 focused update incorporated into the ACC/AHA 2006
guidelines for the management of patients with valvular heart disease: a
report of the American college of cardiology/American heart association
task force on practice guidelines (writing committee to revise the 1998
guidelines for the management of patients with valvular heart disease).
Endorsed by the society of cardiovascular anesthesiologists, society for
cardiovascular angiography and interventions, and society of thoracic
surgeons. J Am Coll Cardiol 2008, 52:e1–e142.
doi:10.1186/1749-8090-8-185
Cite this article as: Kwon et al.: Acute thrombosis of bioprosthetic mitral
valve. Journal of Cardiothoracic Surgery 2013 8:185.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
